See more : Sino-Synergy Hydrogen Energy (9663.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Camurus AB (publ) (CAMRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Camurus AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Hua Nan Financial Holdings Co., Ltd. (2880.TW) Income Statement Analysis – Financial Results
- China Gem Holdings Limited (1191.HK) Income Statement Analysis – Financial Results
- Citizens Financial Group, Inc. (CFG-PD) Income Statement Analysis – Financial Results
- pferdewetten.de AG (EMH.DE) Income Statement Analysis – Financial Results
- Andromeda Metals Limited (ANDMF) Income Statement Analysis – Financial Results
Camurus AB (publ) (CAMRF)
About Camurus AB (publ)
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.72B | 956.34M | 600.57M | 336.00M | 105.61M | 49.32M | 54.31M | 113.74M | 154.80M | 208.21M | 197.72M | 95.20M |
| Cost of Revenue | 122.35M | 103.27M | 85.35M | 35.28M | 23.29M | 6.82M | 1.36M | 2.14M | 237.00K | 656.00K | 1.58M | 3.32M |
| Gross Profit | 1.59B | 853.08M | 515.22M | 300.71M | 82.32M | 42.50M | 52.95M | 111.60M | 154.56M | 207.55M | 196.14M | 91.88M |
| Gross Profit Ratio | 92.87% | 89.20% | 85.79% | 89.50% | 77.95% | 86.17% | 97.50% | 98.12% | 99.85% | 99.68% | 99.20% | 96.51% |
| Research & Development | 637.70M | 473.76M | 388.69M | 238.68M | 249.23M | 207.66M | 222.94M | 172.08M | 153.08M | 114.15M | 52.68M | 54.82M |
| General & Administrative | 48.63M | 35.25M | 27.56M | 97.58M | 23.47M | 22.00M | 26.59M | 17.99M | 11.93M | 22.17M | 17.78M | 14.51M |
| Selling & Marketing | 375.82M | 273.54M | 212.25M | 171.82M | 170.54M | 100.88M | 45.89M | 24.74M | 19.41M | 11.40M | 3.82M | 2.39M |
| SG&A | 424.45M | 308.79M | 239.81M | 269.40M | 194.01M | 122.88M | 72.48M | 42.72M | 31.35M | 33.57M | 21.60M | 16.89M |
| Other Expenses | 6.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.00K | 101.00K | 44.00K |
| Operating Expenses | 1.07B | 781.81M | 627.58M | 507.28M | 442.41M | 330.28M | 295.33M | 214.74M | 358.01M | 147.66M | 74.17M | 71.66M |
| Cost & Expenses | 1.19B | 885.08M | 712.93M | 542.57M | 465.69M | 337.10M | 296.69M | 216.88M | 358.25M | 148.31M | 75.75M | 74.99M |
| Interest Income | 24.72M | 2.70M | 171.00K | 194.00K | 43.00K | 175.00K | 174.00K | 95.00K | 2.00K | 394.00K | 73.00K | 1.00K |
| Interest Expense | 1.28M | 1.53M | 1.37M | 1.54M | 1.59M | 25.00K | 18.00K | 1.00M | 166.00K | 170.00K | 121.00K | 902.00K |
| Depreciation & Amortization | 13.99M | 12.94M | 12.68M | 8.46M | 6.93M | 2.37M | 4.09M | 3.52M | 3.55M | 1.43M | 814.00K | 693.00K |
| EBITDA | 564.57M | 80.63M | -97.72M | -193.49M | -350.97M | -282.59M | -239.26M | -98.83M | -200.55M | 64.14M | 128.20M | 19.46M |
| EBITDA Ratio | 32.88% | 8.43% | -16.27% | -57.59% | -332.34% | -572.97% | -440.56% | -86.90% | -129.56% | 30.81% | 64.84% | 20.44% |
| Operating Income | 525.90M | 71.96M | -110.57M | -205.23M | -360.02M | -287.22M | -243.52M | -102.45M | -204.10M | 62.32M | 127.32M | 18.76M |
| Operating Income Ratio | 30.63% | 7.52% | -18.41% | -61.08% | -340.91% | -582.34% | -448.41% | -90.08% | -131.85% | 29.93% | 64.39% | 19.71% |
| Total Other Income/Expenses | 23.40M | 1.17M | -1.19M | -1.35M | -1.48M | 711.00K | -991.00K | -219.00K | -164.00K | 2.65M | 5.30M | -901.00K |
| Income Before Tax | 549.30M | 73.13M | -111.77M | -206.58M | -361.56M | -287.07M | -243.37M | -103.36M | -204.27M | 62.54M | 127.27M | 17.86M |
| Income Before Tax Ratio | 31.99% | 7.65% | -18.61% | -61.48% | -342.37% | -582.04% | -448.13% | -90.88% | -131.96% | 30.04% | 64.37% | 18.76% |
| Income Tax Expense | 117.86M | 17.57M | -21.32M | -39.31M | -71.70M | -52.39M | -52.79M | -22.37M | -44.73M | 14.20M | 28.03M | 4.54M |
| Net Income | 431.44M | 55.55M | -90.45M | -167.27M | -289.87M | -234.68M | -190.57M | -80.99M | -159.54M | 48.35M | 99.24M | 13.32M |
| Net Income Ratio | 25.13% | 5.81% | -15.06% | -49.78% | -274.48% | -475.81% | -350.91% | -71.21% | -103.06% | 23.22% | 50.19% | 13.99% |
| EPS | 7.50 | 1.01 | -1.66 | -3.18 | -6.23 | -5.77 | -4.68 | -1.99 | -5.51 | 1.18 | 2.43 | 0.33 |
| EPS Diluted | 7.50 | 1.01 | -1.66 | -3.18 | -6.23 | -5.58 | -4.58 | -1.98 | -3.92 | 1.18 | 2.43 | 0.33 |
| Weighted Avg Shares Out | 57.53M | 55.07M | 54.45M | 52.68M | 46.50M | 40.67M | 40.72M | 40.72M | 28.94M | 40.91M | 40.91M | 40.91M |
| Weighted Avg Shares Out (Dil) | 57.50M | 55.07M | 54.45M | 52.68M | 46.50M | 42.06M | 41.57M | 40.95M | 40.72M | 40.91M | 40.91M | 40.91M |
US FDA declines to approve Camurus' rare hormone disorder drug
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Source: https://incomestatements.info
Category: Stock Reports